4Moving Biotech, a spin-off of 4P-Pharma dedicated to facing the global challenge of knee osteoarthritis, announces that it has reached a significant milestone by completing patient recruitment for its LASARE Phase I clinical trial.

The Phase I trial is designed as a multi-center, randomized, double-blind, placebo-controlled study aimed at investigating the safety, tolerability, and pharmacokinetics of Liraglutide, which is administered via intra-articular injection.Thirty-four patients have been randomized across 3 sites in the EU country of Belgium

"This is an important step in our efforts to rapidly translate our drug candidate into a safe and effective therapy. 4P004 offers hope for preventing long-term disability and improving the patient's life.” said Prof. Francis Berenbaum, Chief Medical Officer of 4Moving Biotech.

‍

Click to read Press Release : here

‍

‍